MIST System for Simultaneous Parallel Intracellular Delivery & Transfection

用于同时并行细胞内递送的 MIST 系统

• 批准号: 8904689
• 负责人: Paul K. Olson
• 金额: $ 41.98万
• 依托单位: OPENCELL TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-05 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8904689
• 关键词: Address; Area; Back; Biological Products; Cell Line; Cells; Characteristics; Collaborations; DNA; Development; Electronics; Electrophoresis; Electroporation; Enzymes; Gene Transfer; Goals; Health; Image; Injection of therapeutic agent; Laboratories; Lipofectamine; Measures; Mediating; Methods; Microarray Analysis; Molds; Nucleic Acids; Outcome; Peptide antibodies; Performance; Pharmaceutical Preparations; Phase; Population; Production; Protocols documentation; Research Personnel; Sampling; Small Business Innovation Research Grant; Solutions; Staging; Stem Cell Research; Stem cells; System; Systems Development; Techniques; Technology; Therapeutic Human Experimentation; Time; Transfection; Treatment outcome; Vision; Work; base; cell type; cost; cost effective; design; gene therapy; imaging agent; improved; innovation; instrument; macromolecule; monocyte; nanomaterials; progenitor; prototype; sample collection; screening; tool; uptake

DESCRIPTION (provided by applicant): Alternative nanomaterial and gene transfer solutions are needed to access the potential held in intracellular imaging, biopharmaceuticals, gene therapy and stem cell research. Delivery of small and macromolecules- including nucleic acids, drug molecules, imaging agents, peptides, antibodies and enzymes-into cells is critical to realizing their full potential in a rnge of research and therapeutic applications. Unfortunately, efficient intracellular delivery and transfection continue to elude researchers working with primary and stem cells in emerging application areas. OpenCell's vision is to create new intracellular delivery tools that enable researchers in emerging application areas to work with "difficult-to-transfect" cells for studies that are not currently possible. Our core technology, the Electrosonic Actuation Microarray (EAM), offers researchers a cost-effective and simple-to-use solution to uniform and scalable treatment of entire cell populations on a cell-by-cell basis. Multple Integrated Sample Treatment (MIST)-the subject of this project proposal-addresses cost and performance deficiencies of available methods by incorporating the innovative features of the EAM technology into a multichannel format. In addition, MIST uniquely streamlines protocol optimization and large-scale screening by evaluating treatment outcomes for multiple experimental conditions, including operating parameters and sample compositions, in parallel. During the Phase I project, a MIST prototype achieved biomolecule delivery performance equal to that of our single-sample STEAM system in a 4-channel format, without cross-contamination between channels. We have recently demonstrated advantages of our core technology for large molecule delivery (including in difficult-to- transfect primary monocytes) and for improving transfection outcomes with combined-mode treatment. It is anticipated that these advantages will carry over to the production MIST system. The primary objectives of this SBIR Phase II project are design, manufacture and characterization o a production-ready MIST instrument. To achieve these objectives, (1) MIST systems with stand-alone electronics and disposable multichannel cartridges for mechanoporation and DNA electrophoresis will be developed, and (2) transfection protocol optimization will be demonstrated, along with a comparison of relevant assessment criteria with our single-sample STEAM system and competing technologies.

描述（由申请人提供）：需要替代纳米材料和基因转移解决方案，以获得细胞内成像，生物制药，基因治疗和干细胞研究的潜力。将小分子和大分子（包括核酸、药物分子、显像剂、多肽、抗体和酶）输送到细胞中，对于在一系列研究和治疗应用中充分发挥其潜力至关重要。不幸的是，有效的细胞内传递和转染继续逃避研究人员与原代和干细胞在新兴应用领域的工作。OpenCell的愿景是创建新的细胞内传递工具，使新兴应用领域的研究人员能够使用“难以转染”的细胞进行目前不可能进行的研究。我们的核心技术，电子驱动